Glaucoma Awareness

A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.

In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.

The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.

Mahmoud A. Khaimi, MD, developed a minimally invasive glaucoma surgery known as ab-interno canaloplasty as a treatment option between topical therapies and invasive surgery. The technique continues to prove its value.

The company’s IOPerfect combines artificial intelligence in a VR-like headset to allow tele-diagnosis and remote monitoring of glaucoma.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Investigators in Australia are developing a new rapid screening test for glaucoma that could help advance early detection of the disease.

A coalition of vision groups held a briefing on Capitol Hill this week to educate legislators on increasing incidence of myopia and the associated cost burden.

To mark World Sight Day, Nanodropper Inc. has developed a pay-it-forward Nanodropper Adaptor program, allowing anyone to donate devices to a pool for distribution to patients in need.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

New strategies are needed to rethink how we treat glaucoma to do more than just manage eye pressure—to actually restore vision by promoting the survival of retinal ganglion cells and their axons.

There’s no shortage of diet programs—Paleo, Mediterranean, intermittent fasting—all claiming to be the best option for a healthy life. Research has shown that poor lifestyle choices, including unhealthy diets, contribute to many diseases and that simply adhering to good nutrition can even prevent some health issues.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.

George Waring IV, MD serves as guest host for ‘History and Evolution of Contemporary Refractive Surgery’

A clinical trial of NCX 470 will evaluate the drug for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

New World Medical relied on feedback from surgeons in the development of the device, which was registered with the FDA in October.

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Researchers must weigh emotional, financial, and reputational considerations

Trabeculectomy may offer better results with more severe glaucoma

Technology is off to a good start, but improvements still needed

Diagnostic and monitoring advances in glaucoma need fine-tuning

With an eye on innovation, money is driving research of new therapies and devices.

Industry develops creative approaches to help increase patient medication adherence

Panel discusses IOP monitoring, drug delivery, data collection

For many physicians, “moral injury” may be actual issue